π£ VC round data is live. Check it out!
- Public Comps
- MeiraGTx
MeiraGTx Valuation Multiples
Discover revenue and EBITDA valuation multiples for MeiraGTx and similar public comparables like AprilBio, Akums Drugs and Pharma, Marksans Pharma, Gen Δ°laΓ§ and more.
MeiraGTx Overview
About MeiraGTx
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Founded
2018
HQ

Employees
425
Website
Financials (LTM)
EV
$921M
Valuation Multiples
Start free trialMeiraGTx Financials
MeiraGTx reported last 12-month revenue of $71M.
In the same LTM period, MeiraGTx generated $68M in gross profit and had net loss of ($149M).
Revenue (LTM)
MeiraGTx P&L
In the most recent fiscal year, MeiraGTx reported revenue of $81M and EBITDA of ($89M).
MeiraGTx is unprofitable as of last fiscal year, with gross margin of 94%, EBITDA margin of (110%), and net margin of (140%).
Financial data powered by Morningstar, Inc.
MeiraGTx Stock Performance
MeiraGTx has current market cap of $898M, and enterprise value of $921M.
Market Cap Evolution
MeiraGTx's stock price is $9.70.
MeiraGTx share price increased by 5.2% in the last 30 days, and by 89.5% in the last year.
MeiraGTx has an EPS (earnings per share) of $-1.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $921M | $898M | 3.1% | 5.2% | 28.3% | 89.5% | $-1.23 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMeiraGTx Valuation Multiples
MeiraGTx trades at 13.0x EV/Revenue multiple, and (10.3x) EV/EBITDA.
EV / Revenue (LTM)
MeiraGTx Financial Valuation Multiples
As of May 5, 2026, MeiraGTx has market cap of $898M and EV of $921M.
MeiraGTx has a P/E ratio of (6.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified MeiraGTx Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


MeiraGTx Margins & Growth Rates
In the most recent fiscal year, MeiraGTx reported gross margin of 94%, EBITDA margin of (110%), and net margin of (140%).
MeiraGTx Margins
MeiraGTx Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
MeiraGTx Operational KPIs
MeiraGTx's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.4M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
MeiraGTx Competitors
MeiraGTx competitors include AprilBio, Akums Drugs and Pharma, Marksans Pharma, Gen Δ°laΓ§, CytomX Therapeutics, Alto Neuroscience, Allergy Therapuetics, LB Pharmaceuticals, Janux Therapeutics and ARS Pharmaceuticals.
Most MeiraGTx public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 65.3x | 75.5x | 103.4x | 138.9x | |||
| 1.7x | 1.6x | 13.2x | 13.3x | |||
| 3.2x | 2.8x | 13.8x | 14.5x | |||
| 2.1x | β | 13.9x | β | |||
| 10.2x | 13.5x | (37.1x) | (12.7x) | |||
| β | β | (12.2x) | (9.5x) | |||
| 12.1x | 10.8x | (27.6x) | (23.0x) | |||
| β | β | (20.7x) | β | |||
This data is available for Pro users. Sign up to see all MeiraGTx competitors and their valuation data. Start Free Trial | ||||||
MeiraGTx Funding History
Before going public, MeiraGTx raised $8M in total equity funding, across 2 rounds.
Last private valuation of MeiraGTx was $65M, after raising $5M in March 2018 from Essex Bio-Technology.
MeiraGTx Funding Rounds
MeiraGTx M&A Activity
MeiraGTx has acquired 2 companies to date.
Last acquisition by MeiraGTx was on October 17th 2019. MeiraGTx acquired MeiraGTx for $1M (EV/Revenue multiple of ).
Latest Acquisitions by MeiraGTx
| Description | MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union. | β |
| HQ Country | β | |
| HQ City | Amsterdam | β |
| Deal Date | 17 Oct 2019 | 5 Oct 2018 |
| Valuation | $1M | $24M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all MeiraGTx acquisitions and their M&A valuation multiples. Start Free Trial | ||
MeiraGTx Investment Activity
MeiraGTx has invested in 1 company to date.
Latest investment by MeiraGTx was on September 30th 2025. MeiraGTx invested in Hologen Neuro AI in their $30M Strategic investment round (EV/Revenue multiple of ).
Latest Investments by MeiraGTx
| Description | Hologen Neuro AI is a joint venture between MeiraGTx and Hologen developing AAV-GAD gene therapies for neurological disorders. London and New York-based, the company advances clinical trials for Parkinson's disease treatment via adeno-associated virus vectors expressing GAD enzyme. Hologen Neuro AI's platform targets GABAergic neurons to restore motor function. Phase 1 studies report safety in 20 patients with dosing at multiple brain sites. |
| HQ Country | |
| HQ City | London |
| Deal Date | 30 Sep 2025 |
| Round | Strategic investment |
| Raised | $30M |
| Investors | MeiraGTx |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all MeiraGTx investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout MeiraGTx
| When was MeiraGTx founded? | MeiraGTx was founded in 2018. |
| Where is MeiraGTx headquartered? | MeiraGTx is headquartered in United Kingdom. |
| How many employees does MeiraGTx have? | As of today, MeiraGTx has over 425 employees. |
| Who is the CEO of MeiraGTx? | MeiraGTx's CEO is Alexandria Forbes. |
| Is MeiraGTx publicly listed? | Yes, MeiraGTx is a public company listed on Nasdaq. |
| What is the stock symbol of MeiraGTx? | MeiraGTx trades under MGTX ticker. |
| When did MeiraGTx go public? | MeiraGTx went public in 2018. |
| Who are competitors of MeiraGTx? | MeiraGTx main competitors include AprilBio, Akums Drugs and Pharma, Marksans Pharma, Gen Δ°laΓ§, CytomX Therapeutics, Alto Neuroscience, Allergy Therapuetics, LB Pharmaceuticals, Janux Therapeutics, ARS Pharmaceuticals. |
| What is the current market cap of MeiraGTx? | MeiraGTx's current market cap is $898M. |
| What is the current revenue of MeiraGTx? | MeiraGTx's last 12 months revenue is $71M. |
| What is the current revenue growth of MeiraGTx? | MeiraGTx revenue growth (NTM/LTM) is (5%). |
| What is the current EV/Revenue multiple of MeiraGTx? | Current revenue multiple of MeiraGTx is 13.0x. |
| Is MeiraGTx profitable? | No, MeiraGTx is not profitable. |
| What is the current net income of MeiraGTx? | MeiraGTx's last 12 months net income is ($149M). |
| How many companies MeiraGTx has acquired to date? | As of May 2026, MeiraGTx has acquired 2 companies. |
| What was the largest acquisition by MeiraGTx? | $24M acquisition of Vector Neurosciences on 5th October 2018 was the largest M&A MeiraGTx has done to date. |
| What companies MeiraGTx acquired? | MeiraGTx acquired Vector Neurosciences and MeiraGTx. |
| In how many companies MeiraGTx has invested to date? | As of May 2026, MeiraGTx has invested in 1 company. |
| What was the last MeiraGTx investment? | On 30th September 2025 MeiraGTx invested in Hologen Neuro AI, participating in a $30M Strategic investment round. |
| In what companies MeiraGTx invested in? | MeiraGTx invested in Hologen Neuro AI. |
See public comps similar to MeiraGTx
Lists including MeiraGTx
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
